VolitionRx Limited (NYSE:VNRX) Forecasted to Earn Q2 2024 Earnings of ($0.09) Per Share

VolitionRx Limited (NYSE:VNRX) – Research analysts at Zacks Small Cap lifted their Q2 2024 earnings estimates for shares of VolitionRx in a research report issued to clients and investors on Tuesday, June 25th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.09) per share for the quarter, up from their previous forecast of ($0.10). The consensus estimate for VolitionRx’s current full-year earnings is ($0.34) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.05) EPS and FY2024 earnings at ($0.29) EPS.

VolitionRx (NYSE:VNRX) last posted its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million.

Several other analysts have also issued reports on VNRX. Cantor Fitzgerald restated an “overweight” rating and issued a $2.50 price target on shares of VolitionRx in a research report on Thursday, May 16th. StockNews.com began coverage on shares of VolitionRx in a research report on Friday, June 21st. They issued a “sell” rating on the stock.

VolitionRx Trading Down 5.3 %

NYSE:VNRX opened at $0.63 on Thursday. VolitionRx has a 1 year low of $0.55 and a 1 year high of $1.55. The firm’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.84.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.